Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2013 16:00 ET | Source: Trius Therapeutics, Inc.

Trius to Present at Future Leaders Conference

SAN DIEGO, April 2, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
March 25, 2013 07:00 ET | Source: Trius Therapeutics, Inc.

Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections

Tedizolid Met All Primary and Secondary Efficacy Outcomes Designated by the FDA and EMA NDA Filing Expected Second Half of This Year SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius...
March 12, 2013 16:00 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics Reports 2012 Fourth Quarter and Full Year 2012 Financial Results

SAN DIEGO, March 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
February 12, 2013 16:31 ET | Source: Trius Therapeutics, Inc.

Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA

SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious...
January 23, 2013 08:00 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering

SAN DIEGO, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its previously announced public offering of common stock that priced on...
January 18, 2013 08:00 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics, Inc. Prices Public Offering of Common Stock

SAN DIEGO, Jan. 18, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock at a price...
January 17, 2013 16:15 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering....
January 07, 2013 08:00 ET | Source: Trius Therapeutics, Inc.

Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation From FDA

SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious...
December 10, 2012 08:00 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening...
November 14, 2012 16:01 ET | Source: Trius Therapeutics, Inc.

Trius Therapeutics Ranked Number 42 Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500(TM)

SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right